• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Anthony G. Letai, MD, PHD

Associate Professor, Department of Medicine, Harvard Medical School

Associate Professor of Medicine, Hematologic Neoplasia/Malignancies, Dana-Farber Cancer Institute

Contact Info

Anthony Letai
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 530B
Phone: 617-632-2348
Fax: 617-582-8160
anthony_letai@dfci.harvard.edu

Assistant

Not Available.

DF/HCC Program Affiliation

Lymphoma and Myeloma
Leukemia

Research Abstract

My laboratory investigates the role of apoptotic dysfunction in tumor maintenance. Members of the BCL-2 family of proteins are critical adjudicators of death decisions. We are studying how interactions among anti-apoptotic members (including BCL-2, BCL-XL, MCL-1, BFL-1/A1, and BCL-w) and BH3-only pro-apoptotic members (including BID, BAD, BIM, BIK, PUMA, NOXA, BMF, and Hari-Kiri) can determine cancer cell survival. We are also investigating mimetics of BH3 domains derived from these proteins (including peptides and small molecules) as inhibitors of BCL-2 and the other anti-apoptotic proteins. We utilize a conditional transgenic mouse model of a BCL-2 dependent leukemia. We also study the mechanisms of mitochondrial dysfunction associated with apoptosis in normal and cancer cells. Our goal is to define the dependence of cancer cells on apoptotic dysfunction, and to target this dysfunction to specifically kill cancer cell.

Publications

View All Publications